Companies · Biotechnology

e-Nicotine Technology, Inc.

DRAPER · Biotechnology

Diligence memoA one-page analyst read on e-Nicotine Technology, Inc. — recommendation, valuation, rhythm, risks.
$7.0M
Total raised · real
3
Rounds
0.2×
Latest step-up
Top 52%
Sector rank · raised
Seed
Latest stage · inferred · Wed Oct 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

e-Nicotine Technology, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.27× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Dormant
  • Last raise 11.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

e-Nicotine Technology, Inc. is one of 4293 Biotechnology companies tracked from DRAPER. By capital raised it ranks mid-pack (ahead of 49% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2013-08-15 Raised $4.0M (real) Modeled valuation $177M (est)$4.0M$177MSeed2013Seed · 2013-08-15 Raised $2.6M (real) Modeled valuation $116M (est)$2.6M$116MSeed2013Seed · 2014-10-22 Raised $400K (real) Modeled valuation $18M (est)$400K$18MSeed2014+$2.6M+$400KCumulative $7.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$4.0M · 2013
Seed extension$2.6M · 2013
Seed extension$400K · 2014

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$17.8M
Base estimate est.
$288K
Conservative case
$139.4M
Upside case
$2.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $176.6M · 2013-08-152013Seed · modeled $115.9M · 2013-08-15Seed · modeled $17.8M · 2014-10-222014
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
11.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$5.9M/yr
Capital velocity
12.9 yr
On record since
2013
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$7.0M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.2× of median
This company$400K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$17.8M
Sector median$64.2M

Raised more than 49% of sector peers (real $). Modeled value above 27% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #110 of 122.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Harpoon Medical, Inc. · Seed Raised $7.8M · modeled $173.2M (est)Admittance Technologies, Inc. · Seed Raised $3.9M · modeled $173.0M (est)Bell Biosystems, Inc. · Seed Raised $6.2M · modeled $169.2M (est)Nexstim Plc · Seed Raised $3.7M · modeled $166.4M (est)Iontera, Inc. · Seed Raised $16.8M · modeled $164.2M (est)Monteris Medical Inc · Seed Raised $9.0M · modeled $163.1M (est)Abzena plc · Seed Raised $4.3M · modeled $160.0M (est)Alkahest, Inc. · Seed Raised $3.5M · modeled $155.4M (est)ONCoPEP, Inc. · Seed Raised $12.7M · modeled $153.5M (est)Cal-X Stars Business Accelerator, Inc. · Seed Raised $3.4M · modeled $151.4M (est)QT Holdings Corp. · Seed Raised $3.8M · modeled $145.9M (est)Insight Genetics, Inc. · Seed Raised $5.5M · modeled $135.4M (est)e-Nicotine Technology, Inc. (this company) Raised $7.0M · modeled $17.8M (est)e-Nicotine Technology, Inc.
CompanyStageRaised · realValue · estvs peer med.
Harpoon Medical, Inc.Seed$7.8M$173.2M2.59×
Admittance Technologies, Inc.Seed$3.9M$173.0M2.59×
Bell Biosystems, Inc.Seed$6.2M$169.2M2.53×
Nexstim PlcSeed$3.7M$166.4M2.49×
Iontera, Inc.Seed$16.8M$164.2M2.46×
Monteris Medical IncSeed$9.0M$163.1M2.44×
Abzena plcSeed$4.3M$160.0M2.40×
Alkahest, Inc.Seed$3.5M$155.4M2.33×
ONCoPEP, Inc.Seed$12.7M$153.5M2.30×
Cal-X Stars Business Accelerator, Inc.Seed$3.4M$151.4M2.27×
QT Holdings Corp.Seed$3.8M$145.9M2.19×
Insight Genetics, Inc.Seed$5.5M$135.4M2.03×
e-Nicotine Technology, Inc. this companySeed$7.0M$17.8M0.27×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$4.0M2013-08-15$19.9M$176.6M90%
Seed$2.6M2013-08-15$13.1M$115.9M90%
Seed$400K2014-10-22$2.0M$17.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$4.0M2013-08-15
    • First recorded raise — entered as Seed.
  2. Seed$2.6M2013-08-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
  3. Seed$400K2014-10-22
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 6.5× smaller than the prior — bridge or down round.
Intelligence
2015 ~Q2
Modeled next raise · ~7mo cadence
$400K
Modeled next size est.range $400K$640K
0.2×
Last step-up
$5.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jeffrey Williams9 other2013-08
Richard Brenner5 other2013-08
Michael Hufford1 other2013-08
Christopher B Munday2013-08
Don B Watkins2013-08
Fraser B Bullock2013-08
Martin Wensley2013-08
Registry & provenance

e-Nicotine Technology, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1584922
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lucigen CorpBiotechnologySeed$7.0M$98.8Mnetwork1 shared operator · same sector · same stage
Virica Biotech Inc.BiotechnologySeed$7.0M$18.6Msame sector · same stage
Tarpon Biosystems Inc.BiotechnologySeed$7.0M$13.1Msame sector · same stage
E25Bio Inc.BiotechnologySeed$6.8M$13.7Msame sector · same stage
Imaging3 IncBiotechnologySeed$6.6M$19.1Msame sector · same stage
Biocurity Pharmaceuticals Inc.BiotechnologySeed$7.6M$13.3Msame sector · same stage
Arterica Inc.BiotechnologySeed$6.3M$22.8Msame sector · same stage
Innovative Cardiovascular Solutions, LLCBiotechnologySeed$7.9M$13.0Msame sector · same stage
Frequently asked
How much funding has e-Nicotine Technology, Inc. raised?
e-Nicotine Technology, Inc. has raised approximately $7.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is e-Nicotine Technology, Inc.'s estimated valuation?
Provath's modeled valuation for e-Nicotine Technology, Inc. is approximately $17.8M (modeled range $288K–$139.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is e-Nicotine Technology, Inc. at?
e-Nicotine Technology, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Oct 22.
What does e-Nicotine Technology, Inc. do and where is it based?
e-Nicotine Technology, Inc. operates in the Biotechnology sector, based in DRAPER.
Explore related

See where e-Nicotine Technology, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at e-Nicotine Technology, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.